Curium Expands Through Acquisition of Monrol
Deal News | Mar 29, 2025 | Globenewswire
Curium Pharma, a leader in nuclear medicine, has completed its acquisition of Eczacıbaşı-Monrol Nuclear Products Co. This acquisition aims to significantly expand Curium's capacity for producing Lutetium-177, a pivotal isotope in nuclear medicine, particularly for treating prostate cancer and neuroendocrine tumors. The acquisition aligns with Curium’s strategy to broaden its pipeline and product portfolio through Monrol's innovative research and development. Monrol's addition enhances Curium's geographical reach, bolstering its PET and SPECT framework by adding facilities in Eastern Europe and MENA regions. This strategic expansion includes the implementation of Monrol's Ga-68 generator, pending regulatory approvals, and supports Curium’s vertical manufacturing and distribution. By taking advantage of Monrol's resourceful workforce and advanced infrastructure, Curium aims to extend its impact on nuclear diagnostic and therapeutic solutions globally.
Sectors
- Nuclear Medicine
- Pharmaceuticals
Geography
- France – Curium Pharma is a French company, and it’s the main entity involved in the transaction.
- Turkey – Monrol is based in Istanbul, Turkey, and it is the target company in the acquisition.
- Europe – The expansion covers multiple locations across Western and Eastern Europe, highlighting the regional focus of the acquisition.
- MENA – The acquisition increases Curium's footprint in the Middle East and North Africa, addressing market expansion in these areas.
Industry
- Nuclear Medicine – The article is concentrated on companies involved in nuclear medicine, focusing on the production and distribution of radiopharmaceuticals.
- Pharmaceuticals – The acquisition will bolster the product pipeline with new drug candidates in prostate cancer and neuroendocrine tumors, marking the significance in pharmaceuticals.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Curium Pharma | Acquirer | Company | A leading company in nuclear medicine, developing, manufacturing, and distributing radiopharmaceuticals. |
| Eczacıbaşı-Monrol Nuclear Products Co. | Target Company | Company | A leading nuclear medicine company based in Istanbul, Turkey, specializing in innovative R&D and manufacturing capabilities. |
| Eczacıbaşı Pharmaceutical and Industrial Investment | Vendor | Company | Parent company associated with Monrol, participating in the sale. |
| Chaitanya Tatineni | CEO of Curium International Markets | Person | Commented on the strategic significance of the acquisition for Curium. |
| Aydin Kucuk | General Manager of Monrol | Person | Expressed enthusiasm about joining Curium and working on nuclear medicine solutions. |
| Emin Fadıllıoğlu | CEO of Eczacıbaşı Pharmaceutical and Industrial Investment | Person | Commented on Monrol's development and integration into Curium. |